Next Article in Journal
Soil and Leaf Nutrients Drivers on the Chemical Composition of the Essential Oil of Siparuna muricata (Ruiz & Pav.) A. DC. from Ecuador
Previous Article in Journal
Inter- and Intra-Molecular Organocatalysis of SN2 Fluorination by Crown Ether: Kinetics and Quantum Chemical Analysis
Review

The Therapeutic Potential of Psilocybin

1
Biotech R & D Institute, University of the West Indies, Mona 99999, Jamaica
2
Vilotos Pharmaceuticals Inc., Baltimore, MD 21202, USA
3
Flavocure Biotech Inc., Baltimore, MD 21202, USA
4
Institute of Human Virology (IHV), University of Maryland School of Medicine, Baltimore, MD 21202, USA
5
The Psyence Group, Toronto, ON M5J 2J1, Canada
6
Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
7
Caribbean School of Medical Sciences, Kingston 99999, Jamaica
*
Author to whom correspondence should be addressed.
Academic Editor: Raffaele Capasso
Molecules 2021, 26(10), 2948; https://doi.org/10.3390/molecules26102948
Received: 21 March 2021 / Revised: 18 April 2021 / Accepted: 22 April 2021 / Published: 15 May 2021
The psychedelic effects of some plants and fungi have been known and deliberately exploited by humans for thousands of years. Fungi, particularly mushrooms, are the principal source of naturally occurring psychedelics. The mushroom extract, psilocybin has historically been used as a psychedelic agent for religious and spiritual ceremonies, as well as a therapeutic option for neuropsychiatric conditions. Psychedelic use was largely associated with the “hippie” counterculture movement, which, in turn, resulted in a growing, and still lingering, negative stigmatization for psychedelics. As a result, in 1970, the U.S. government rescheduled psychedelics as Schedule 1 drugs, ultimately ending scientific research on psychedelics. This prohibition on psychedelic drug research significantly delayed advances in medical knowledge on the therapeutic uses of agents such as psilocybin. A 2004 pilot study from the University of California, Los Angeles, exploring the potential of psilocybin treatment in patients with advanced-stage cancer managed to reignite interest and significantly renewed efforts in psilocybin research, heralding a new age in exploration for psychedelic therapy. Since then, significant advances have been made in characterizing the chemical properties of psilocybin as well as its therapeutic uses. This review will explore the potential of psilocybin in the treatment of neuropsychiatry-related conditions, examining recent advances as well as current research. This is not a systematic review. View Full-Text
Keywords: magic mushrooms; psilocybin; psychedelic; neuropharmaceuticals; neurotherapeutics; addiction; anxiety; depression; cancer; psychopharmacology magic mushrooms; psilocybin; psychedelic; neuropharmaceuticals; neurotherapeutics; addiction; anxiety; depression; cancer; psychopharmacology
Show Figures

Figure 1

MDPI and ACS Style

Lowe, H.; Toyang, N.; Steele, B.; Valentine, H.; Grant, J.; Ali, A.; Ngwa, W.; Gordon, L. The Therapeutic Potential of Psilocybin. Molecules 2021, 26, 2948. https://doi.org/10.3390/molecules26102948

AMA Style

Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A, Ngwa W, Gordon L. The Therapeutic Potential of Psilocybin. Molecules. 2021; 26(10):2948. https://doi.org/10.3390/molecules26102948

Chicago/Turabian Style

Lowe, Henry, Ngeh Toyang, Blair Steele, Henkel Valentine, Justin Grant, Amza Ali, Wilfred Ngwa, and Lorenzo Gordon. 2021. "The Therapeutic Potential of Psilocybin" Molecules 26, no. 10: 2948. https://doi.org/10.3390/molecules26102948

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop